Roger Kornberg, who chairs ChromaDex's Scientific Advisory Board, commented, "Demonstrating that NR is an effective precursor to increase NAD+ in humans has significant positive implications and may be a cornerstone to developing solutions to delay or reverse the effects of aging, obesity and disease.
founder and CEO of ChromaDex, commented, "We believe the confirmation that a single dose of NR increases NAD+ in humans is a landmark result and a significant bridge between the numerous animal studies previously conducted that have demonstrated not only an increase in NAD+, but also a broad range of therapeutic benefits.
For the past 13 years, we at Life Extension[R] have been searching for an efficient way for aging humans to affordably boost their cellular NAD+ levels.
Now, after more than a decade of searching, an effective NAD+ cell-boosting technology has finally become available.
NAD+ is known to play a key role in human cells by activating proteins called sirtuins that help the cells survive under stress.
The researchers believe that quickly increasing the NAD+ levels may help to activate the sirtuin levels in the cells and prevent cell death.
The challenge we at Life Extension have faced over the past 13 years is finding an efficient way for aging humans to affordably boost their NAD+ cellular levels.
In 2001, one of our researchers developed an effective NAD+ boosting sublingual lozenge, but it only maintained stability for a short time period.
Jaksch continued, "Confirming that NR leads to a meaningful increase in NAD+ in humans should also be an incredible driver with respect building consumer awareness for NIAGEN(TM) as well as increased interest for the ingredient by both consumer products companies as well as pharmaceutical companies interested in therapeutic applications of NIAGEN(TM).
NAD+ is arguably the most important cellular co-factor for the improvement of mitochondrial performance and energy metabolism.
They say that more than one biosynthetic pathway is usually involved in NAD+ production.
In humans, according to the team, NAD+ can be obtained through several different complex pathways, and not all of the pathways utilize NAD+ synthetase to produce NAD+.